The government is providing £2 million to give more patients access to proven innovations through the Accelerated Access Collaborative (AAC).
Seven innovative technology areas were identified by the AAC that improve patients’ lives but are not currently available to everyone who could benefit. This first batch of ‘rapid uptake’ products was selected by leaders in the health and care system, and includes a range of treatments for conditions such as cancer, heart disease and multiple sclerosis.
Supporting the ‘rapid uptake’ products will not only help 500,000 patients to access new treatments, they will also provide cost savings to the NHS of £30 million, while helping to reinforce the UK’s position as a global leader in health innovation.
The products will be spread through the AHSN Network’s Innovation Exchange, which matches solutions to the needs of their local health and care systems.
The rapid uptake products are:
- Heartflow – A non-invasive personalized cardiac test that reduces the need for unnecessary procedures
- Placental growth factor (PIG-F) based testing for suspected pre-eclampsia – tests for early diagnosis of pre-eclampsia in pregnant women, which if unmonitored, can cause serious complications for mother and baby.
- PCSK9 inhibitors for treatment of primary hypercholesterolaemia and mixed dyslipidaemia – cost-effective drugs that significantly lower cholesterol.
- High sensitivity troponin tests for early rule out of myocardial infarction (acute) – diagnostic tests that detect whether or not a patient is at risk or previously had a heart attack.
- Quantitative faecal immunochemical tests for colorectal cancer – diagnostic tests that reduce referrals for patients with suspected colorectal cancer.
- Cladribine (brand name: Mavenclad) for treating highly active relapsing-remitting multiple sclerosis in adults – a drug for multiple sclerosis with a novel mode of action, high efficacy and a low treatment and monitoring burden
- Urolift for lower urinary tract symptoms of benign prostatic hyperplasia.